{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:49:19Z","timestamp":1762249759245},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Dasatinib, as an oral multi-targeted inhibitor of BCR-ABL and SRC family kinases,\nhas been widely used for the treatment of Philadelphia Chromosome Positive Leukemias in imatinib-acquired\nresistance and intolerance. The study aimed to develop and validate a simple and robust assay with a small volume\nof plasma based on liquid chromatography coupled with tandem mass spectrometry to determine the concentration\nof dasatinib and to investigate the impact of the cytochrome 3A4 inhibitors, including ketoconazole,\nvoriconazole, itraconazole and posaconazole, on the pharmacokinetics of dasatinib in rats.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Thirty rats were divided randomly into five groups, control group (0.5% carboxymethylcellulose sodium),\nketoconazole (30 mg\/kg) group, voriconazole group (30 mg\/kg), itraconazole group (30 mg\/kg) and posaconazole\ngroup (30 mg\/kg). After 150 \u03bcL blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, and\n48 h and precipitated with acetonitrile, the plasma concentration of dasatinib was determined through Fluoro-\nPhenyl column (150 mm\u00d72.1 mm, 3 \u03bcm) in a positive ionization mode.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The results suggested that ketoconazole, voriconazole, and posaconazole could increase the AUC0-t of\ndasatinib to varying degrees while significantly reducing its clearance. However, there was no significant impact\non the pharmacokinetics of dasatinib, co-administered with itraconazole except for the CL and MRT0-t of\ndasatinib. Additionally, voriconazole could significantly increase Cmax of dasatinib by approximately 4.12 fold.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These data indicated that ketoconazole, posaconazole and voriconazole should be cautiously co-administered\nwith dasatinib or close therapeutic drug monitoring of dasatinib concentration, which might cause\nthe drug-drug interaction.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200221666201022140656","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T04:15:32Z","timestamp":1603426532000},"page":"1022-1030","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS"],"prefix":"10.2174","volume":"21","author":[{"given":"Xingxian","family":"Luo","sequence":"first","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuecai","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taifeng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning,China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"Weisberg E.","year":"2007","unstructured":"Weisberg E.; Manley P.W.; Cowan-Jacob S.W.; Hochhaus A.; Griffin J.D.; Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007,7(5),345-356","journal-title":"Nat Rev Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","volume":"212","author":"Lindauer M.","year":"2018","unstructured":"Lindauer M.; Hochhaus A.; Dasatinib. Recent Results Cancer Res 2018,212,29-68","journal-title":"Recent Results Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1111\/jcmm.14980","volume":"24","author":"Corrales-S&#xE1;nchez V.","year":"2020","unstructured":"Corrales-S&#xE1;nchez V.; Noblejas-L&#xF3;pez M.D.M.; Nieto-Jim&#xE9;nez C.; P&#xE9;rez-Pe&#xF1;a J.; Montero J.C.; Burgos M.; Gal&#xE1;n-Moya E.M.; Pandiella A.; Oca&#xF1;a A.; Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. J Cell Mol Med 2020,24(5),3117-3127","journal-title":"J Cell Mol Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.18632\/oncotarget.27462","volume":"11","author":"Montenegro R.C.","year":"2020","unstructured":"Montenegro R.C.; Howarth A.; Ceroni A.; Fedele V.; Farran B.; Mesquita F.P.; Frejno M.; Berger B.T.; Heinzlmeir S.; Sailem H.Z.; Tesch R.; Ebner D.; Knapp S.; Burbano R.; Kuster B.; M&#xFC;ller S.; Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. Oncotarget 2020,11(5),535-549","journal-title":"Oncotarget"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"Hickson L.J.","year":"2019","unstructured":"Hickson L.J.; Langhi Prata L.G.P.; Bobart S.A.; Evans T.K.; Giorgadze N.; Hashmi S.K.; Herrmann S.M.; Jensen M.D.; Jia Q.; Jordan K.L.; Kellogg T.A.; Khosla S.; Koerber D.M.; Lagnado A.B.; Lawson D.K.; LeBrasseur N.K.; Lerman L.O.; McDonald K.M.; McKenzie T.J.; Passos J.F.; Pignolo R.J.; Pirtskhalava T.; Saadiq I.M.; Schaefer K.K.; Textor S.C.; Victorelli S.G.; Volkman T.L.; Xue A.; Wentworth M.A.; Wissler Gerdes E.O.; Zhu Y.; Tchkonia T.; Kirkland J.L.; Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 2019,47,446-456","journal-title":"EBioMedicine"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"Kamath A.V.","year":"2008","unstructured":"Kamath A.V.; Wang J.; Lee F.Y.; Marathe P.H.; Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008,61(3),365-376","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1124\/dmd.107.018267","volume":"36","author":"Christopher L.J.","year":"2008","unstructured":"Christopher L.J.; Cui D.; Wu C.; Luo R.; Manning J.A.; Bonacorsi S.J.; Lago M.; Allentoff A.; Lee F.Y.; McCann B.; Galbraith S.; Reitberg D.P.; He K.; Barros A.; Blackwood-Chirchir A.; Humphreys W.G.; Iyer R.A.; Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008,36(7),1357-1364","journal-title":"Drug Metab Dispos"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3109\/03639045.2015.1004182","volume":"41","author":"Zhou Y.","year":"2015","unstructured":"Zhou Y.; Wang S.; Ding T.; Wu M.; Geng P.; Zhang Q.; Ma J.; Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS\/MS. Drug Dev Ind Pharm 2015,41(12),1948-1953","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/cncr.24927","volume":"116","author":"Johnson F.M.","year":"2010","unstructured":"Johnson F.M.; Agrawal S.; Burris H.; Rosen L.; Dhillon N.; Hong D.; Blackwood-Chirchir A.; Luo F.R.; Sy O.; Kaul S.; Chiappori A.A.; Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010,116(6),1582-1591","journal-title":"Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/00498254.2018.1473662","volume":"49","year":"2019","unstructured":"Luo X, Li T, Yu Z, Xue X, Zhao H, Li N, Ma L, Yang C, Huang L, Feng W. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica 2019,49(7),753-61","journal-title":"Xenobiotica"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1248\/bpb.b14-00564","volume":"37","author":"Yamamoto H.","year":"2014","unstructured":"Yamamoto H.; Habu Y.; Yano I.; Ozaki J.; Kimura Y.; Sato E.; Shida A.; Fukatsu S.; Matsubara K.; Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Biol Pharm Bull 2014,37(12),1990-1993","journal-title":"Biol Pharm Bull"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","volume":"166","author":"Xu R.A.","year":"2019","unstructured":"Xu R.A.; Lin Q.; Qiu X.; Chen J.; Shao Y.; Hu G.; Lin G.; UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. J Pharm Biomed Anal 2019,166,6-12","journal-title":"J Pharm Biomed Anal"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jchromb.2018.05.042","volume":"1092","author":"Dong X.","year":"2018","unstructured":"Dong X.; Zhang Y.; Meng Z.; Zhu X.; Gan H.; Gu R.; Wu Z.; Li J.; Zheng Y.; Yang B.; Dou G.; A LC-MS\/MS method to monitor the concentration of HYD-PEP06, a RGD-modified Endostar mimetic peptide in rat blood. J Chromatogr B Analyt Technol Biomed Life Sci 2018,1092,296-305","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=14","year":"2018","unstructured":"Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug AdministrationAvailable from: 2018"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1055\/s-0032-1327702","volume":"62","author":"Thappali S.R.","year":"2012","unstructured":"Thappali S.R.; Varanasi K.V.; Veeraraghavan S.; Vakkalanka S.K.; Khagga M.; Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS\/MS: method validation and application to pharmacokinetic study. Arzneimittelforschung 2012,62(12),624-630","journal-title":"Arzneimittelforschung"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2011.10.003","volume":"59","year":"2012","unstructured":"D'Avolio A, Simiele M, De Francia S, Ariaudo A, Baietto L, Cusato J, Fava C, Saglio G, Di Carlo F, Di Perri G. HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J Pharm Biomed Anal 2012,59,109-16","journal-title":"J Pharm Biomed Anal"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2011.09.008","volume":"58","year":"2012","unstructured":"Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, Stouffer B. A validated LC\u2013MS\/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 2012,58,130-5","journal-title":"J Pharm Biomed Anal"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","volume":"208","author":"Koller D.","year":"2020","unstructured":"Koller D.; Vaitsekhovich V.; Mba C.; Steegmann J.L.; Zubiaur P.; Abad-Santos F.; Wojnicz A.; Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. Talanta 2020,208,120450","journal-title":"Talanta"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"121928","DOI":"10.1016\/j.jchromb.2019.121928","volume":"1137","author":"Mukai Y.","year":"2020","unstructured":"Mukai Y.; Yoshida T.; Kondo T.; Inotsume N.; Toda T.; Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton\u2019s tyrosine kinase inhibitors and their three active metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2020,1137,121928","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"121851","DOI":"10.1016\/j.jchromb.2019.121851","volume":"1136","author":"Ezzeldin E.","year":"2020","unstructured":"Ezzeldin E.; Iqbal M.; Herqash R.N.; ElNahhas T.; Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS\/MS method and its application to human microsomal metabolic stability study. J Chromatogr B Analyt Technol Biomed Life Sci 2020,1136,121851","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"Niwa T.","year":"2005","unstructured":"Niwa T.; Shiraga T.; Takagi A.; Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005,28(9),1805-1808","journal-title":"Biol Pharm Bull"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00498254.2011.631224","volume":"42","author":"Zhang S","year":"2012","unstructured":"Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R; Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012,42(5),409-16","journal-title":"Xenobiotica"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"Hartmann J.T.","year":"2009","unstructured":"Hartmann J.T.; Haap M.; Kopp H.G.; Lipp H.P.; Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009,10(5),470-481","journal-title":"Curr Drug Metab"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"Hegedus C.","year":"2009","unstructured":"Hegedus C.; Ozvegy-Laczka C.; Ap&#xE1;ti A.; Mag&#xF3;csi M.; N&#xE9;met K.; Orfi L.; K&#xE9;ri G.; Katona M.; Tak&#xE1;ts Z.; V&#xE1;radi A.; Szak&#xE1;cs G.; Sarkadi B.; Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009,158(4),1153-1164","journal-title":"Br J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bdd.2022","volume":"37","author":"D\u2019Cunha R.","year":"2016","unstructured":"D\u2019Cunha R.; Bae S.; Murry D.J.; An G.; TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos 2016,37(7),397-408","journal-title":"Biopharm Drug Dispos"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1124\/dmd.107.020255","volume":"36","author":"Wang L.","year":"2008","unstructured":"Wang L.; Christopher L.J.; Cui D.; Li W.; Iyer R.; Humphreys W.G.; Zhang D.; Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008,36(9),1828-1839","journal-title":"Drug Metab Dispos"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/bpb.28.316","volume":"28","author":"Kageyama M.","year":"2005","unstructured":"Kageyama M.; Namiki H.; Fukushima H.; Ito Y.; Shibata N.; Takada K.; In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 2005,28(2),316-322","journal-title":"Biol Pharm Bull"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3109\/03639045.2014.983930","volume":"41","author":"Wang L.","year":"2015","unstructured":"Wang L.; Wang S.; Chen M.; Chen X.; Lin Y.; Hu X.; Huang X.; Li X.; Hu G.; Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Drug Dev Ind Pharm 2015,41(10),1661-1666","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40262-013-0070-9","volume":"52","author":"Frechen S.","year":"2013","unstructured":"Frechen S.; Junge L.; Saari T.I.; Suleiman A.A.; Rokitta D.; Neuvonen P.J.; Olkkola K.T.; Fuhr U.; A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin Pharmacokinet 2013,52(9),763-781","journal-title":"Clin Pharmacokinet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/03639045.2019.1569042","volume":"45","author":"Lou D.","year":"2019","unstructured":"Lou D.; Cui X.; Bao S.S.; Sun W.; Pan W.H.; Chen M.C.; Dong Y.Y.; Hu G.X.; Chen R.J.; Wang Z.; Effects of ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of apatinib in rats. Drug Dev Ind Pharm 2019,45(4),689-693","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2217\/pgs.11.18","volume":"12","author":"Mikus G.","year":"2011","unstructured":"Mikus G.; Scholz I.M.; Weiss J.; Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011,12(6),861-872","journal-title":"Pharmacogenomics"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/j.transproceed.2003.10.058","volume":"35","author":"Florea N.R.","year":"2003","unstructured":"Florea N.R.; Capitano B.; Nightingale C.H.; Hull D.; Leitz G.J.; Nicolau D.P.; Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003,35(8),2873-2877","journal-title":"Transplant Proc"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1046\/j.1397-3142.2003.00103.x","volume":"7","author":"Mahnke C.B.","year":"2003","unstructured":"Mahnke C.B.; Sutton R.M.; Venkataramanan R.; Michaels M.; Kurland G.; Boyle G.J.; Law Y.M.; Miller S.A.; Pigula F.A.; Gandhi S.; Webber S.A.; Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant 2003,7(6),474-478","journal-title":"Pediatr Transplant"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3109\/03639045.2013.838582","volume":"40","author":"Lin G.","year":"2014","unstructured":"Lin G.; Wang C.; Qiu X.; Wang Z.; Han A.; Xu T.; Kan X.; Hu G.; Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm 2014,40(12),1616-1622","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/00498254.2018.1425510","volume":"49","author":"Krasulova K","year":"2019","unstructured":"Krasulova K; Dvorak Z; Anzenbacher P; In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A. Xenobiotica 2019,49(1),36-42","journal-title":"Xenobiotica"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1185\/03007990802644209","volume":"25","author":"Moton A.","year":"2009","unstructured":"Moton A.; Ma L.; Krishna G.; Martinho M.; Seiberling M.; McLeod J.; Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009,25(3),701-707","journal-title":"Curr Med Res Opin"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","volume":"29","author":"Billaud E.M.","year":"2009","unstructured":"Billaud E.M.; Antoine C.; Berge M.; Abboud I.; Lefeuvre S.; Benammar M.; Glotz D.; Management of metabolic cytochrome P450 3A4 drug- drug interaction between everolimus and azole antifungals in a renal transplant patient. Clin Drug Investig 2009,29(7),481-486","journal-title":"Clin Drug Investig"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0169-409X(02)00171-0","volume":"55","author":"Lin J.H.","year":"2003","unstructured":"Lin J.H.; Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003,55(1),53-81","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1177\/1078155218801055","volume":"25","author":"Shumaker AC","year":"2019","unstructured":"Shumaker AC; Bullard HM; Churpek J; Knoebel RW; Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein. J Oncol Pharm Pract 2019,25(7),1758-1761","journal-title":"J Oncol Pharm Pract"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1389200219666181003142036","volume":"20","author":"Akamine Y.","year":"2019","unstructured":"Akamine Y.; Yasui-Furukori N.; Uno T.; Drug-drug interactions of P-gp substrates unrelated to CYP metabolism. Curr Drug Metab 2019,20(2),124-129","journal-title":"Curr Drug Metab"},{"key":"ref=41","year":"2020","unstructured":"U.S. Food and Drug. In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme-and Transporter-Mediated Drug Interactions Guidance for Industry.Available from: 2020"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/1389200033489389","volume":"4","author":"Benet L.Z.","year":"2003","unstructured":"Benet L.Z.; Cummins C.L.; Wu C.Y.; Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003,4(5),393-398","journal-title":"Curr Drug Metab"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"Miura M.","year":"2015","unstructured":"Miura M.; Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 2015,38(5),645-654","journal-title":"Biol Pharm Bull"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187111\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T05:31:00Z","timestamp":1649482260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187111\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666201022140656","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}